Recently, Finnish orthopedic device company Bioretec announced that its biodegradable implant RemeOs DrillPin, based on magnesium alloy platform technology, has been granted the "Breakthrough Device Designation" by the U.S. Food and Drug Administration (FDA). This product is suitable for fracture fragment fixation in both pediatric and adult patients, particularly covering metaphyseal fractures in children aged ≥2 years with open growth plates, including trans-growth plate (transphyseal) fixation indications, which have long been considered high-risk scenarios in clinical practice.
This marks the third product from Bioretec to receive the FDA Breakthrough Device Designation. Previously, its RemeOs trauma screws and intervertebral fusion cages were granted this designation in 2021 and 2024, respectively. Among them, the trauma screws have already received support from the U.S. Medicare and Medicaid Services (CMS) for reimbursement, establishing a clear commercialization foundation. These series of advancements signify that Bioretec's magnesium-based biodegradable metal platform is progressing from "material innovation" to a stage recognized by clinical, regulatory, and payment systems.
# Clinical Background: Why Has There Been a Long-Term Lack of Ideal Solutions for Trans-Growth Plate Fixation
In the field of pediatric orthopedics, fracture treatment has always faced a core contradiction: the need for sufficiently stable internal fixation while avoiding long-term damage to the growth plate. Traditional metal implants (such as steel pins and titanium alloy screws) can meet the fixation requirements in terms of mechanical properties. However, once they cross the growth plate, they may pose risks of growth disturbances, skeletal asymmetry, or even deformities. Therefore, in clinical practice a secondary removal surgery is often required after fracture healing. For pediatric patients, this means an additional anesthesia procedure, surgical trauma, and infection risk, increasing the burden on families and the healthcare system.
Although absorbable polymer materials offer advantages in terms of "no need for removal," they still have significant limitations in load-bearing capacity, fixation stability, and adaptability to complex fractures.
Thus, a solution that "can provide metal-level fixation strength and naturally exit the body after healing" has long been considered an ideal goal in pediatric orthopedics, yet mature and available products have been lacking.
# Product and Technology: The Engineering Logic Behind RemeOs DrillPin
RemeOs DrillPin is not based on traditional absorbable materials but rather on a biodegradable magnesium alloy metal platform. The key to this technological approach lies in simultaneously addressing the two major challenges of "strength" and "exit mechanism."
From a mechanical perspective, RemeOs magnesium alloy provides fixation strength close to that of traditional metals in the early stages of implantation, meeting the stability requirements for initial fracture healing. As the bone healing process progresses, the material gradually undergoes controlled degradation, with its mechanical support capacity matching the rhythm of bone reconstruction, avoiding "premature destabilization" or "long-term foreign body retention."
From a biological perspective, the ions released during magnesium degradation in the body are believed to have a certain osteoinductive promoting effect, aiding bone formation and remodeling. Compared to inert metal implants, this "bioactivity" makes it closer to a natural participant in the bone healing process.
In terms of clinical use, RemeOs DrillPin offers good imaging compatibility, not interfering with X-ray or CT assessments, and possesses MRI conditional safety attributes, reducing restrictions during postoperative follow-up. More importantly, its characteristic of requiring no secondary removal surgery is particularly crucial for pediatric patients and is precisely why it holds high hopes in trans-growth plate fixation scenarios.
# Company Perspective: From a Single Product to a Platform Approach
Bioretec's long-term positioning is to reshape the complete lifecycle of "fixation-healing-exit" in orthopedic surgery through fully biodegradable implants. Around this goal, the company has developed unique capabilities in biointerface engineering for active implants, systematically integrating material science, mechanical properties, and bone biological processes.
From trauma screws to DrillPin and then to intervertebral fusion cages, the RemeOs series of products has covered high-value scenarios in trauma orthopedics, pediatric orthopedics, and spine, providing continuous validation of the feasibility of magnesium-based biodegradable metals in broader orthopedic applications.
# Observation: Degradable Metals Are Entering the Most Conservative Clinical Field
From an industry perspective, the significance of RemeOs DrillPin receiving the Breakthrough Device Designation extends beyond a single product. Pediatric orthopedics, especially treatments involving the growth plate, has always been one of the most cautious and conservative clinical fields. The fact that a new material and approach have received clear regulatory support in this field sends a strong signal.
This means that degradable metal technology is transitioning from the discussion stage of "whether the material is feasible" to the practical testing stage of "whether it can be incorporated into standard treatment pathways." It is no longer just a substitute for traditional metals but is redefining the endpoint form of fracture fixation—naturally exiting after fulfilling its mission rather than permanently remaining. (Bone Future)
International Mg Society